Home Tags IMMU-132

Tag: IMMU-132

U.S. Food and Drug Administration Rejects Sacituzumab Govitecan

The U.S. Food and Drug Administration (FDA) has rejected sacituzumab govitecan also known as IMMU-132, a novel, investigational, antibody-drug conjugate or ADC consisting of...

2017 San Antonio Breast Cancer Symposium will Highlight Several Antibody-Drug Conjugates...

This year’s San Antonio Breast Cancer Symposium (SABCS) is taking place on December 5-9th, 2017, and it is expected to bring in a broad...
ESMO 2017 - 3

Interim Phase II Results with Sacituzumab Govitecan in Pretreated Metastatic Urothelial...

Results from an interim Phase II study with sacituzumab govitecan (IMMU-132) shows that the investigational agent is active in patients with metastatic urothelial cancer...

Sacituzumab govitecan (IMMU-132) Demonstrates Therapeutic Potential in the Treatment of Metastatic...

Two prominent cancer journals have published phase II clinical trial results with sacituzumab govitecan (IMMU-132; Immunomedics) in a total of 104 patients with lung...

Antitumor Effect of Sacituzumab Govitecan in Triple-Negative Breast Cancer Can be...

Based on a pre-clinical study, treatment of patients sacituzumab govitecan, also known as  IMMU-132 (Immunomedics), in patients with metastatic triple-negative breast cancer (mTNBC) has...

Enhancing Activity of Sacituzumab Govitecan in SN-38-Resistant Cancer

Adding an inhibitor of ATP-binding cassette (ABC) transporters to sacituzumab govitecan increased the median survival of mice bearing a SN-38-resistant human gastric cancer cell...

ASCO 2016 Emphasizes Collective Wisdom: The Future of Patient-Centered Care and...

Only a few weeks until the start of the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). This year’s ASCO, taking...

American Association for Cancer Research (AACR) – What to Expect at...

This year, the American Association for Cancer Research (AACR) will host their annual meeting from April 16 to 20, 2016 in the Ernest N....

Breakthrough Therapy Designation for Sacituzumab Govitecan in Triple-negative Breast Cancer

Sacituzumab govitecan, also known as IMMU-132, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients...

Sacituzumab govitecan (IMMU-132) Shows Positive Interim Phase II Results

Sacituzumab govitecan also known as IMMU-132, an antibody-drug conjugate being developed by Immunomedics, a clinical-stage biopharmaceutical company, continues to produce durable responses in patients with...

DOWNLOAD